View Published SNOMED CT Subset Metadata

QOF Prescribable beta-adrenoceptor blockers excluding those used in HF


Subset Name :   
QOF Prescribable beta-adrenoceptor blockers excluding those used in HF
Subset Original Id :   
635101000001131
Subset Type :   
Realm Concept

Refset FSN :   
Quality and Outcomes Framework general practice extraction - beta-adrenoceptor blockers excluding those used in heart failure prescribable within general practice simple reference set (foundation metadata concept)
Refset Id :   
12465401000001109
Refset Type :   
Simple

Subset Description :
All VMPs and AMPs associated with the following VTMs: Metoprolol, Pindolol, Propranolol, Acebutolol, Esmolol, Nadolol, Timolol, Atenolol, Celiprolol, Atenolol + Bendroflumethiazide, Atenolol + Nifedipine, Nadolol + Bendroflumethiazide, Pindolol + Clopamide, Acebutolol + Hydrochlorothiazide, Propranolol + Bendroflumethiazide, Timolol + Bendroflumethiazide, Timolol + Travoprost, Timolol + Amiloride + Hydrochlorothiazide, Co-tenidone, Oxprenolol, Co-Prenoxzide, Labetalol, Metoprolol + Hydrochlorothiazide, Betaxolol and Sotalol. VMP Generic Kalten and associated AMPs. The subset also excludes all VMPs and AMPs that have any of the following drug forms: Eye drops, Ear drops, Eye ointment, Eye gel, Ear/eye drops solution and Ear/eye/nose drops solution. This subset, as currently published, supports the NHS England QOF business rules for 2018-2019. This subset may contain invalid concepts.

Status

Subset Status :   
Supported
Subset Status Date :   
Mar 30, 2016
Owner (Organisation name) :   
NHS Digital

Purpose and Scope

Usage 1 :

   
Usage Type :    
Intended
Usage Description :    
Intended for secondary uses purposes. Management Information to support counts for establishing Quality and Outcomes Framework points used to determine Practice QOF payments. QOF Indicators Supported: Indicator HF004: In those patients with a current diagnosis of heart failure due to left ventricular systolic dysfunction who are currently treated with an ACE-I or ARB, the percentage of patients who are additionally currently treated with a beta-blocker licensed for heart failure. Historically this cluster has been included for a retired indicator, but was also used to ensure that non-licensed beta-adrenoceptor blockers were identified and excluded If this section becomes updated I would expect the indicator rules would be updated to just look for the licensed beta-adrenoceptor drugs. NICE clinical guidelines & advice: See guidance for treatment of heart failure and chronic heart disease These subsets are created using the XML format dm+d data and so within these subsets a small number of concepts are inactive (status 2 or 10) in the International Release. The origin of these inactive concepts is the native XML dm+d and they are now inactive in the new International Release due to natural movement and updating of the International Release content. Work is underway to update the dm+d concepts to the new International release identifiers; at this point this mismatch will be resolved. If using the dm+d in SNOMED CT format the International Release relationships will enable migration to the replacement concept. The subsets as published in the current release data are applicable to the QOF year 2018-2019.
Geographic Usage :    
England
Usage Category:    
 Quality Outcome Framework Prescribable


Scope :

   
Inclusion Criteria :   
Age group - any age; Gender - not specified; Sex - not specified
Subject Category :   
Prescribing; Chemicals and Drugs

Publication

Subset Release Category :   
UK Drug Extension
Language :   
en
Folder Name :   
QOF
File Name :   
der1_SubsetMembers_QOFPresBetaAdBloExForHF_GB1000001_YYYYMMDD

Subset Licence Type :   
IHTSDO SNOMED CT® Licence; UKTC SNOMED CT® Licence; Open Government Licence

Metadata Version :   
8.0
Last Updated :   
Sep 7, 2018

Related Links

Subset download with descriptions :

UK Drug Extension releases